ADMP stock


Adamis Pharmaceuticals Corp: Naloxone Could Be a Significant Growth Candidate, Says Elliot Wilbur

With the tremendous focus on the opioid crisis, Raymond James’ Elliot Wilbur sees exciting potential for Adamis.

Adamis Pharmaceuticals Corp (ADMP): Analyst Sees Meaningful Revenue Gains Waiting in the Wings for Sympjepi Asset

Now that ADMP has submitted a PAS for its pediatric version of Symjepi, an epipnephrine injection cheaper than Mylan’s EpiPen, FBR’s Andrew D’silva sees a potential approval with less risk than the original version.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts